(Sharecast News) - RUA Life Sciences said in an update on Friday that it expected to report a smaller EBITDA loss, broadly reaching breakeven on an adjusted basis, after revenue growth in its UK contract development and manufacturing and biomaterials businesses offset weaker trading at Abiss.
The AIM-traded medical device group...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE